Coreline Soft announced on February 5 that it is accelerating its entry into the global remote diagnosis market using world-class artificial intelligence (AI) technology. The company has already made initial strides in the remote diagnosis field through collaboration with international corporations and recently succeeded in obtaining major international certifications, such as the U.S. Health Insurance Portability and Accountability Act (HIPAA) and the European General Data Protection Regulation (GDPR). Coreline Soft plans to leverage these achievements and overseas certifications to expand the supply of its AI software and drive growth in performance.
Coreline Soft entered the market last May by forming a strategic partnership with DMC Healthcare, a UK specialist in remote diagnosis, based on its proprietary AI software, AVIEW LCS Plus. DMC is a solution provider for the UK government-led lung cancer screening project and has multiple references and a local network in the remote diagnosis sector.
The remote diagnosis market is rapidly growing, particularly in advanced countries such as the United States, the United Kingdom, and Japan. Since the COVID-19 pandemic, demand in related fields has surged, and governments worldwide are actively supporting remote diagnosis. Unlike traditional medical facility supply, remote diagnosis has the potential to significantly expand the applicable patient population, leading to substantial performance contributions, as AI software sales vary based on patient numbers.
Coreline Soft intends to accelerate its approach to the global remote diagnosis market, building on accumulated references in major European countries and the U.S. As global remote diagnostic companies actively expand their market presence, Coreline Soft expects an increase in software supply, having recently proven its AI technology to be superior to that of the world's leading companies through international journal publications.
A Coreline Soft representative stated, “There is rapidly growing demand for remote diagnosis in developed countries like the UK due to a shortage of medical staff and facilities. Unlike domestically, this market is expanding rapidly.” The representative added, “With the accelerated adoption of AI software overseas, we plan to expand our market strategy based on AI software approvals and remote diagnosis references covering most of the global market, including U.S. FDA and European CE certifications.”
He added, "Notably, our main AI product at Coreline Soft has recently outperformed the lung cancer screening solutions of global competitors in performance benchmarks. As a result, we anticipate beginning large-scale supplies to government-led projects and remote diagnosis companies." He concluded, "Our goal is to enhance performance growth through AI software by strengthening our presence in the lucrative remote diagnosis market."
